Eyepoint Pharmaceuticals Inc (EYPT) — Cash Flow Reinvestment Rate

Latest as of June 2023: 0.25x

Eyepoint Pharmaceuticals Inc (EYPT) has a Cash Flow Reinvestment Rate of 0.25x as of June 2023, reinvesting $14.26 Million (capex $396.00K plus investments $13.86 Million) from operating cash flow of $57.02 Million. See how much free cash does Eyepoint Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.25x
(Capex + Investments) / Operating CF

Total Reinvested

$14.26 Million
Capex + Investments

Operating Cash Flow

$57.02 Million
USD

Capital Expenditures

$396.00K
USD

Eyepoint Pharmaceuticals Inc Cash Flow Reinvestment Rate (2010–2023)

Historical reinvestment intensity for Eyepoint Pharmaceuticals Inc across 3 annual periods. For the full cash flow conversion analysis, see Eyepoint Pharmaceuticals Inc cash flow conversion.

Annual Cash Flow Reinvestment Rate for Eyepoint Pharmaceuticals Inc (2010–2023)

Year-by-year capital reinvestment analysis for Eyepoint Pharmaceuticals Inc. See how financially flexible is Eyepoint Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2023 3.63x $6.80 Million $1.88 Million $3.48 Million ▲ +727.8%
2015 0.44x $4.51 Million $10.30 Million $161.00K ▲ +28804.5%
2010 0.00x $15.00K $9.90 Million $15.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow